ChemicalBook CAS数据库列表 KIRA8 (AMG-18)
KIRA8 (AMG-18)
- CAS号:1630086-20-2
- 英文名:Amgen IRE1α Inhibitor
- 中文名:KIRA8 (AMG-18)
- CBNumber:CB73123772
- 分子式:C31H29ClN6O3S
- 分子量:601.12
- MOL File:1630086-20-2.mol
KIRA8 (AMG-18)化学性质
- 沸点 :812.6±75.0 °C(Predicted)
- 密度 :1.383±0.06 g/cm3(Predicted)
- 储存条件 :Store at -20°C
- 溶解度 :Water:30.0(Max Conc. mg/mL);49.91(Max Conc. mM)
- 形态 :Solid
- 酸度系数(pKa) :7.66±0.30(Predicted)
- 颜色 :Light yellow to yellow
KIRA8 (AMG-18)性质、用途与生产工艺
- 生物活性 Kira8 (AMG-18) 是一种单选择性 IRE1α 抑制剂，可以变构减弱 IRE1α RNase 活性，IC50 为 5.9 nM。
-
靶点
IRE1α
IC50: 5.9 nM (IRE1α RNase) -
体外研究
Kira8 blocks IRE1α oligomerization, and potently inhibits IRE1α RNase activity against XBP1 and Ins2 RNAs. Kira8 more potently reduces IRE1α-driven apoptosis in INS-1 cells than KIRA6 and also reverses XBP1 splicing promoted by GNF-2.
-
体内研究
Male Ins2 +/Akita mice are injected i.p. with KIRA8 (50 mg/kg; daily; for 35 days), significant reduction of hyperglycemia become apparent over several weeks.
One week treatment of pre-diabetic NODs mice with Kira8 (50 mg/kg; i.p.; once a day) leads to significant reductions in islet XBP1 splicing and TXNIP mRNAs, and preserves Ins1/Ins2, BiP and MANF mRNAs.Animal Model: Male Ins2 +/Akita mice Dosage: 50 mg/kg Administration: Injected i.p.; daily; for 35 days Result: Significant reduction of hyperglycemia became apparent over several weeks.
KIRA8 (AMG-18)上下游产品信息
上游原料
下游产品
KIRA8 (AMG-18) 试剂级价格
- 更新日期：2024/11/08
- 产品编号：HY-114368
- 产品名称：Kira8
- CAS编号：
- 包装：1 mg
- 价格：1050元
- 更新日期：2024/11/08
- 产品编号：HY-114368
- 产品名称：KIRA8 (AMG-18) Kira8
- CAS编号：1630086-20-2
- 包装：5 mg
- 价格：2300元
KIRA8 (AMG-18)生产厂家
- 公司名称：TORONTO
- 联系电话：--
- 电子邮件：info@trc-canada.com
- 国家：加拿大
- 产品数：6038
- 优势度：71
